3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Colorectal Neoplasms
5
Colonic Neoplasms
5
Rectal Neoplasms
3
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Urinary Bladder Neoplasms
1
Small Cell Lung Carcinoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
pembrolizumab
20
Gemcitabine
10
Nivolumab
8
Irinotecan
8
atezolizumab
7
durvalumab
6
Docetaxel
6
sargramostim
5
Specimen Handling
5
Magnetic Resonance Spectroscopy
5
Cyclophosphamide
5
130-nm albumin-bound paclitaxel
5
aldesleukin
4
Psychiatric Rehabilitation
4
Leucovorin
4
Ipilimumab
4
Fluorouracil
4
Cisplatin
4
tislelizumab
3
spartalizumab
3
avelumab
3
Topotecan
3
Therapeutics
3
Polymerase Chain Reaction
3
Carboplatin
3
Bevacizumab
3
tremelimumab
2
talazoparib
2
surufatinib
2
regorafenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
In Situ Hybridization, Fluorescence
×
Gastrointestinal
×
Clear all
NCT00900094
2012-02-07
IRB 2000-294
University of Michigan Rogel Cancer Center
Completed
200 enrolled